The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach

DOI10.1111/j.1541-0420.2006.00666.xzbMath1124.62084OpenAlexW2015506353WikidataQ51916813 ScholiaQ51916813MaRDI QIDQ5427414

No author found.

Publication date: 20 November 2007

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1111/j.1541-0420.2006.00666.x

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items

A system for determining maximum tolerated dose in clinical trial ⋮ A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents ⋮ Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials ⋮ gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials ⋮ Generalized Bayes Quantification Learning under Dataset Shift ⋮ Bayesian phase I/II adaptively randomized oncology trials with combined drugs ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Continual reassessment method with multiple toxicity constraints ⋮ On the consistency of the continual reassessment method with multiple toxicity constraints ⋮ Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials ⋮ Risk-Group-Specific Dose Finding Based on an Average Toxicity Score ⋮ Simple benchmark for complex dose finding studies ⋮ Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach

Cites Work

• Unnamed Item
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Curve-Free and Model-Based Continual Reassessment Method Designs
• Design and Analysis of Phase I Clinical Trials
• Pseudo Maximum Likelihood Methods: Theory
• Continual Reassessment Method: A Likelihood Approach
• Semiparametric regression for count data
• Designs foe phase i cancer clinical trials with differentiation of graded toxicity
• Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial